Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Cash & Equivalents (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed Cash & Equivalents for 4 consecutive years, with $34.7 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents fell 38.92% to $34.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $34.7 million through Dec 2025, down 38.92% year-over-year, with the annual reading at $34.7 million for FY2025, 38.92% down from the prior year.
  • Cash & Equivalents for Q4 2025 was $34.7 million at Orchestra BioMed Holdings, down from $74.0 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $126.6 million in Q1 2023, with the low at $735217.0 in Q3 2022.
  • Average Cash & Equivalents over 4 years is $42.4 million, with a median of $30.1 million recorded in 2024.
  • The sharpest move saw Cash & Equivalents skyrocketed 8820.91% in 2023, then plummeted 68.21% in 2025.
  • Over 4 years, Cash & Equivalents stood at $82.6 million in 2022, then rose by 2.5% to $84.6 million in 2023, then tumbled by 32.88% to $56.8 million in 2024, then tumbled by 38.92% to $34.7 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $34.7 million, $74.0 million, and $24.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.